Allergy

The long-term safety and efficacy of treatments for allergy and inflammatory conditions was highlighted at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization Joint Congress.

Genetics and environment both influence allergy risk, but environmental factors play a stronger role in the progression of allergic disease.

Further research is needed to clarify the cost-effectiveness, long-term adherence, and psychosocial impacts of oral immunotherapy.

In this discussion, panelists offer their final thoughts.

In this discussion, panelists explore the potential role of new Bruton tyrosine kinase inhibitors in the treatment landscape for chronic spontaneous urticaria (CSU), evaluating their stages of development and expected impact on treatment algorithms, while also considering future changes in coverage and payer strategies with the emergence of new therapies.

A panel of experts discuss the clinical trials of dupilumab, the resultant data, and the response of the FDA when approval was requested.

A panel of experts discuss the key updates needed in CSU guidelines, as they have not been updated since 2014.

Panelists discuss how 30%-50% of patients with chronic spontaneous urticaria remain symptomatic despite treatment, examining the impact of treatment burdens, the limitations of targeting the IgE pathway, and the need for new therapies addressing the IgG pathway.

A panel of experts discuss using systemic corticosteroids in CSU treatment.

A panel of experts discuss switching between different antihistimines and other medications when treating CSU patients.

Stanley Goldstein, MD, discusses which therapies are typically used initially for CSU patients.

A panel of experts discuss the healthcare specialties that become involved in treating patients with CSU.

Data on new treatments for chronic spontaneous urticaria (CSU) show significant symptom reduction very early during treatment.

Given the lack of efficacy of antihistamines for most patients with chronic spontaneous urticaria (CSU), biologics have changed the entire world of CSU.

While there is treatment for chronic spontaneous urticaria (CSU), there remains a need for newer therapies, explained allergy specialist Jonathan Bernstein, MD.

The chronic nature of the hives affecting patients with chronic spontaneous urticaria (CSU) can really affect all aspects of their lives, including sleep, daily activities, work, and interpersonal relationships.

The chronic and unpredictable nature of chronic spontaneous urticaria (CSU) can cause crippling anxiety around how long the painful symptoms of the disease will last, explained Kristen Willard, a patient advocate with CSU.

The pain of chronic spontaneous urticaria (CSU) can be crippling, explained Kristen Willard, a patient advocate with CSU, who discussed her treatment journey.